Insuman Basal (Insulin Human (Rdna))

Insulin human (rDNA) is a recombinant form of human insulin that binds to insulin receptors on muscle, fat and liver cells. This binding activates intracellular pathways that increase glucose uptake, promote glycogen storage, suppress hepatic glucose production, and facilitate lipid metabolism, thereby lowering blood glucose concentrations.

The dose of Insuman Basal is individualized. A prescriber determines the starting amount and any subsequent adjustments based on the patient’s blood‑glucose readings, body weight, diet, activity level and overall treatment plan. Patients should follow the specific dosing instructions provided by their healthcare provider.

Safety data for Insuman Basal in pregnancy and lactation are limited. It may be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and under close medical supervision. Breastfeeding mothers should consult their physician, as insulin does pass into breast milk in small amounts.

To order Insuman Basal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics) and any necessary import documentation.

Insuman Basal contains recombinant human insulin, whereas many newer basal insulins are insulin analogues with modified amino‑acid sequences that may offer flatter pharmacokinetic profiles. Both provide long‑acting glucose control, but analogue products can have a reduced risk of nocturnal hypoglycaemia in some patients. Choice depends on clinical response, cost, and prescriber preference.

Insuman Basal must be stored at 2‑8 °C (refrigerated) in its original packaging, protected from light. Do not freeze or shake the vial or pen. Once in use, it may be kept at room temperature (up to 30 °C) for a limited period as indicated in the product labeling, but should be discarded after the recommended time.

Insuman Basal is given by subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to avoid lipodystrophy. Patients should be trained on proper technique, needle length, and disposal of sharps, and should follow the dosing schedule prescribed by their healthcare professional.

The most serious risks include severe hypoglycaemia, which can cause loss of consciousness or seizures, and allergic reactions ranging from rash to anaphylaxis. Rarely, patients may develop insulin‑induced edema or hypokalemia. Prompt medical attention is required if any of these serious events occur.

Insuman Basal should not be used by individuals with a known hypersensitivity to human insulin or any excipients in the formulation. It is also contraindicated in patients experiencing severe hypoglycaemia unawareness or those with conditions that preclude insulin therapy without close medical supervision.